biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 24/2021 | 29-06-2021 | Zakończenie certyfikacyjnych badań klinicznych systemu PCR|ONE panel SARS-CoV-2

Previous PostNext Post

Related Posts

29.04.2025

Scope Fluidics Launches Fellowship Program for Young Scientists with Project Budgets of up to PLN 1 Million

0
28.04.2025

Historic Deal Completed, Strategic Innovation Now Advancing – Scope Fluidics Post 2024

0
28.04.2025

European Patent Granted to Bacteromic

0